| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |